Monte Rosa Therapeutics Stock Performance
| GLUE Stock | USD 18.96 0.61 3.12% |
On a scale of 0 to 100, Monte Rosa holds a performance score of 7. The company secures a Beta (Market Risk) of -0.39, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Monte Rosa are expected to decrease at a much lower rate. During the bear market, Monte Rosa is likely to outperform the market. Please check Monte Rosa's sortino ratio, skewness, period momentum indicator, as well as the relationship between the potential upside and rate of daily change , to make a quick decision on whether Monte Rosa's current price movements will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Monte Rosa Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Monte Rosa exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 132.7 M | |
| Total Cashflows From Investing Activities | -44.5 M |
Monte Rosa Relative Risk vs. Return Landscape
If you would invest 1,432 in Monte Rosa Therapeutics on November 13, 2025 and sell it today you would earn a total of 465.00 from holding Monte Rosa Therapeutics or generate 32.47% return on investment over 90 days. Monte Rosa Therapeutics is currently generating 0.6956% in daily expected returns and assumes 7.4394% risk (volatility on return distribution) over the 90 days horizon. In different words, 66% of stocks are less volatile than Monte, and 86% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Monte Rosa Target Price Odds to finish over Current Price
The tendency of Monte Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 18.96 | 90 days | 18.96 | about 44.48 |
Based on a normal probability distribution, the odds of Monte Rosa to move above the current price in 90 days from now is about 44.48 (This Monte Rosa Therapeutics probability density function shows the probability of Monte Stock to fall within a particular range of prices over 90 days) .
Monte Rosa Price Density |
| Price |
Predictive Modules for Monte Rosa
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Monte Rosa Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Monte Rosa's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Monte Rosa Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Monte Rosa is not an exception. The market had few large corrections towards the Monte Rosa's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Monte Rosa Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Monte Rosa within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.72 | |
β | Beta against Dow Jones | -0.39 | |
σ | Overall volatility | 3.46 | |
Ir | Information ratio | 0.08 |
Monte Rosa Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Monte Rosa for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Monte Rosa Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Monte Rosa is way too risky over 90 days horizon | |
| Monte Rosa appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 75.62 M. Net Loss for the year was (72.7 M) with profit before overhead, payroll, taxes, and interest of 50.97 M. | |
| Monte Rosa has a poor financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are owned by institutional investors |
Monte Rosa Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Monte Stock often depends not only on the future outlook of the current and potential Monte Rosa's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Monte Rosa's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 73.9 M | |
| Cash And Short Term Investments | 372.1 M |
Monte Rosa Fundamentals Growth
Monte Stock prices reflect investors' perceptions of the future prospects and financial health of Monte Rosa, and Monte Rosa fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Monte Stock performance.
| Return On Equity | 0.0928 | ||||
| Return On Asset | 0.0137 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | (2.58) % | ||||
| Current Valuation | 1.14 B | ||||
| Shares Outstanding | 76.24 M | ||||
| Price To Earning | 1.91 X | ||||
| Price To Book | 6.07 X | ||||
| Price To Sales | 8.23 X | ||||
| Revenue | 75.62 M | ||||
| EBITDA | (72.99 M) | ||||
| Cash And Equivalents | 294.14 M | ||||
| Cash Per Share | 6.32 X | ||||
| Total Debt | 42.72 M | ||||
| Debt To Equity | 0.16 % | ||||
| Book Value Per Share | 3.98 X | ||||
| Cash Flow From Operations | 42 M | ||||
| Earnings Per Share | 0.32 X | ||||
| Total Asset | 438.73 M | ||||
| Retained Earnings | (438.59 M) | ||||
About Monte Rosa Performance
By analyzing Monte Rosa's fundamental ratios, stakeholders can gain valuable insights into Monte Rosa's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Monte Rosa has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Monte Rosa has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the bodys natural mechanisms to selectively degrade therapeutically relevant proteins. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts. Monte Rosa operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 93 people.Things to note about Monte Rosa Therapeutics performance evaluation
Checking the ongoing alerts about Monte Rosa for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Monte Rosa Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Monte Rosa is way too risky over 90 days horizon | |
| Monte Rosa appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 75.62 M. Net Loss for the year was (72.7 M) with profit before overhead, payroll, taxes, and interest of 50.97 M. | |
| Monte Rosa has a poor financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are owned by institutional investors |
- Analyzing Monte Rosa's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Monte Rosa's stock is overvalued or undervalued compared to its peers.
- Examining Monte Rosa's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Monte Rosa's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Monte Rosa's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Monte Rosa's stock. These opinions can provide insight into Monte Rosa's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Monte Stock analysis
When running Monte Rosa's price analysis, check to measure Monte Rosa's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monte Rosa is operating at the current time. Most of Monte Rosa's value examination focuses on studying past and present price action to predict the probability of Monte Rosa's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monte Rosa's price. Additionally, you may evaluate how the addition of Monte Rosa to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Stocks Directory Find actively traded stocks across global markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |